Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: One-year results of a prospective case series

摘要: Abstract Objective To determine the efficacy of photodynamic therapy (PDT) with verteporfin as a treatment for symptomatic polypoidal choroidal vasculopathy (PCV). Design Prospective consecutive, 2-centered, noncomparative interventional case series. Participants Twenty-one Asian patients 22 eyes presenting serosanguinous maculopathy due to PCV and an initial best-corrected visual acuity (BCVA) 20/40 or worse were recruited prospectively. All had angiographic leakage seen on fluorescein angiograms (FAs) features indocyanine green (ICG) angiography. Methods Intravenous infusion at dose 6 mg/m 2 body surface area over 10 minutes was administered. Five after completion infusion, 689-nm laser applied 83 seconds, light 50 J/cm . The spot size chosen cover polyps surrounding abnormally dilated vessels shown ICG angiography plus extra 1000-μm margin. Photodynamic retreatment performed if from found both repeat FAs regular 3-month follow-up intervals. Main outcome measures proportion stable improved vision 1-year follow-up. Secondary included change in mean BCVA changes clinical total number PDT sessions any complications also recorded. Results Stable achieved 21 (95%) Ten (45%) moderate gain (improved by ≥3 lines), whereas 1 (5%) eye suffered loss (decrease lines). logarithm minimum angle resolution(logMAR) 0.73 0.60, equivalent 1.3 lines improvement. logMAR 12 months statistically significant (Wilcoxon signed-ranks test, P = 0.009). Complete absence regression observed 20 (91%) eyes, respectively. Severe massive subretinal hemorrhage occurred eye; otherwise, there no other serious treatment-related adverse events. Conclusions results treating macular type presentations are encouraging. Further studies longer randomized controlled trials warranted assess long-term safety relative observation modalities.